Show simple item record

dc.contributor.authorErkisa Genel, Merve
dc.contributor.authorAri, Ferda
dc.contributor.authorUlku, Irem
dc.contributor.authorKhodadust, Rouhollah
dc.contributor.authorYar, Yasemin
dc.contributor.authorAcar, Havva Yagci
dc.contributor.authorUlukaya, Engin
dc.date.accessioned2020-09-22T13:00:37Z
dc.date.available2020-09-22T13:00:37Z
dc.date.issued2020en_US
dc.identifier.citationErkisa, M., Arı, F., Ulku, I., Khodadust, R., Yar, Y., Yagci Acar, H., & Ulukaya, E. Etoposide Loaded SPION‐PNIPAM Nanoparticles Improve the in vitro Therapeutic Outcome on Metastatic Prostate Cancer Cells via Enhanced Apoptosis. Chemistry & Biodiversity.en_US
dc.identifier.issn1612-1872
dc.identifier.urihttps://doi.org/10.1002/cbdv.202000607
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1072
dc.descriptionPubmed: 32918383en_US
dc.description.abstractProstate cancer is among the leading causes of death worldwide because its metastatic form is a deadly disease. Therefore, the development of new chemotherapeutics is of immense importance. Nanoparticle technology seems to provide diverse options in this regard. Therefore, poly(N-isopropylacrylamide) (PNIPAM) coated superparamagnetic iron oxide nanoparticles (SPION) loaded with etoposide were prepared in small sizes (57 nm) and with 3.5% drug content to improve the efficiency of etoposide in prostate cancer therapy. Sustained release of the drug was achieved, which found to be sensitive to low pH and high temperature. The anti-growth activity of SPION-PNIPAM-Etoposide formulation against metastatic prostate cancer cells (PC-3, LNCaP) were investigated by SRB assay, then confirmed by ATP assay. Mode of cell death was evaluated by using flow cytometry analyses. A significant improvement of nanoformulated drug was observed at 5-10 μg/ml doses of the drug in both cell lines. More importantly, this formulation enhanced the cytotoxic effect of etoposide on PC-3 cells, which is considered more resistant to etoposide than LNCaP, and reduced the IC 50 by 55% reaching to 4.5 μg drug/ml, which is a very significant improvement in the literature. It was clearly shown that nanoformulated drug provided about 3 fold increases in caspase-dependent early apoptotic cells in PC-3 cells. The novel formulation seems to successfully cause cell death of especially PC-3 metastatic prostate cancer cells. It should therefore be taken into consideration for further animal studies as a novel potent anticancer agent.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1002/cbdv.202000607en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSuperparamagnetic Iron Oxide Nanoparticlesen_US
dc.subjectEtoposideen_US
dc.subjectApoptosisen_US
dc.subjectProstate Canceren_US
dc.subjectDrug Deliveryen_US
dc.titleEtoposide loaded SPION-PNIPAM nanoparticles improve the in vitro therapeutic outcome on metastatic prostate cancer cells via enhanced apoptosisen_US
dc.typearticleen_US
dc.contributor.departmentİstinye Üniversitesi, Rektörlüken_US
dc.contributor.institutionauthorErkisa Genel, Merve
dc.relation.journalChem Biodiversen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record